There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (NASDAQ:ALNY) and Eiger Biopharmaceuticals (NASDAQ:EIGR) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report released today, Madhu Kumar from B.Riley FBR reiterated a Buy rating on Alnylam Pharma, with a price target of $230. The company’s shares opened today at $92.
Kumar noted:
“Friday afternoon, Pharmaceuticals (ALNY) announced the FDA approval of transthyretin (TTR) RNAi drug Onpattro (also known as patisiran) for polyneuropathy (PN) of hereditary TTR amyloidosis (hATTR), with value-based agreement (VBA) alignment for several key U.S. insurers. We remind investors that hATTR-PN constitutes a substantial orphan disease market for which Onpattro is, in our view, a best-in-class therapy. With Onpattro’s U.S. approval, we reiterate our ALNY Buy rating, raise our price target from $210 to $230, and reiterate Alnylam as one of our Out-the-Gate 2018 picks.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.2% and a 52.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $149, representing a 62.0% upside. In a report issued on August 7, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
Eiger Biopharmaceuticals (EIGR)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Eiger Biopharmaceuticals, with a price target of $53. The company’s shares opened today at $9.55.
According to TipRanks.com, Moussatos is a 2-star analyst with an average return of 1.0% and a 42.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $31.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
